Weekly Digest - Feb 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Feb 2024
09 Feb 2024: Bristol Myers Squibb finalizes agreement with SystImmune for BL-B01D1 in ADC
- Bristol Myers Squibb completes Global Strategic License and Collaboration Agreement with SystImmune for BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), enhancing BMS presence in the ADC space
- BL-B01D1 has the potential to treat patients with lung cancer, breast cancer, and additional tumor types, with the opportunity to expand into novel combinations with standard-of-care treatments and Bristol Myers Squibb’s pipeline assets
- Through the agreement, Bristol Myers Squibb and SystImmune will co-develop and co-commercialize BL-B01D1 in the United States. SystImmune has retained exclusive rights in Mainland China and Bristol Myers Squibb has gained an exclusive license in the rest of the world
